Symic reports Phase I/II data for SB-030 in peripheral vascular disease

Symic Bio Inc. (Emeryville, Calif.) reported data from the single-blind, Australian and New Zealand Phase I/II SHIELD trial in

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE